Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), a US-based pharmaceutical company, announced on Wednesday that it has been ranked 25th on the Deloitte Technology Fast 500.

The company was added to the list for growing revenues 7,204% from fiscal year 2019 to 2022.

The firm was ranked eighth of the 87 life science companies honoured this year, placing it among the fastest-growing companies across the life science, technology, media, fintech, and energy sectors in North America.

Jeffrey M Dayno, MD, Harmony Biosciences president and chief executive officer, said, 'Harmony is a growth story and our remarkable success is a testament to the strength of our business and our commitment to delivering novel treatments for people living with rare neurological disorders. It's an honour to be recognised as one of the fastest-growing companies in North America across industry sectors and we look forward to building upon this growth in the future.'